Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,653 across all filing types
Latest filing 2023-07-14 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
关于注射用MCLA-129和甲磺酸贝福替尼胶囊联合用药获得临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a pharmaceutical company about receiving clinical trial approval notices from the National Medical Products Administration (NMPA) for two drugs. It details the clinical trial approval, drug information, and potential impact on the company. The document is short (2345 characters) and serves as an official announcement of regulatory approval rather than a detailed report or financial statement. It does not contain financial data, earnings, or management discussion. It is not a report publication announcement since it is the announcement itself. The content fits best under Regulatory Filings (RNS) as it is a regulatory announcement about clinical trial approvals and related information that does not fit other specific categories.
2023-07-14 Chinese
关于股东股份质押变动的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding changes in the pledge status of shares held by a major shareholder (Ningbo Kaiming Investment Management Partnership) of Betta Pharmaceuticals Co., Ltd. It details the number of shares pledged, the extension of pledge periods, and the risk assessment related to these pledges. There is no financial statement, earnings data, or management discussion of financial results. The document is focused on shareholder share pledge changes, which is a capital structure-related update but specifically about share pledges rather than new financing or capital raising. This fits best under the category of Regulatory Filings (RNS) as it is a regulatory disclosure about share pledge changes and does not fit the more specific categories like Capital/Financing Update (CAP) which usually involves new financing activities, or Major Shareholding Notification (MRQ) which concerns changes in ownership levels crossing thresholds. The document is also relatively short (2089 characters) and is a formal announcement rather than a report or presentation.
2023-07-14 Chinese
关于股东股份质押变动的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement regarding changes in the pledge status of shares held by a major shareholder (宁波凯铭投资管理合伙企业) of 贝达药业股份有限公司. It details the number of shares pledged, the proportion of shares pledged relative to total holdings and company stock, and the risk assessment related to these pledges. There is no financial statement, earnings data, or management discussion of financial results. The document is focused on share pledge changes, which is a capital structure related update. It is not a full financial report, audit, or earnings release. It is not a voting result or board change announcement. The document fits best under the category of Capital/Financing Update (CAP), as it concerns financing activities related to share pledges by shareholders.
2023-06-28 Chinese
关于国家药品监督管理局批准伏罗尼布片上市的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Betta Pharmaceuticals Co., Ltd. regarding the approval by the National Medical Products Administration (国家药品监督管理局) for the marketing of a new drug, Volitinib tablets. It includes details about the drug, its registration, research background, and potential impact on the company. The document is short (1177 characters) and serves as an official announcement of a regulatory approval event rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or detailed management analysis. It is not a report publication announcement since it does not mention any report being published or attached. The content fits best under a Regulatory Filing (RNS) as it is a regulatory announcement about drug approval, which is a material event for the company but does not fit other more specific categories like earnings release or management report.
2023-06-08 Chinese
2022年年度权益分派实施公告
Notice of Dividend Amount Classification · 95% confidence The document is titled as an 'Annual Equity Distribution Implementation Announcement' for the year 2022 by 贝达药业股份有限公司. It details the profit distribution plan approved at the 2022 Annual General Meeting held on May 15, 2023, including cash dividends per share, dividend payment dates, and shareholder eligibility. The document is an announcement of the implementation of the dividend distribution plan that was approved at the AGM, not the AGM materials themselves or the full annual report. It specifically announces the dividend amount, payment method, and relevant dates, which fits the definition of a Notice of Dividend Amount (DIV). The document length is about 2010 characters, which is relatively short and focused on dividend distribution details rather than comprehensive financial data or management discussion. Therefore, the appropriate classification is Notice of Dividend Amount (DIV).
2023-06-07 Chinese
关于国家药品监督管理局批准甲磺酸贝福替尼胶囊上市的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval by the National Medical Products Administration (NMPA) of a new drug (甲磺酸贝福替尼胶囊) for marketing. It details the drug's registration, research background, and potential impact on the company. The document is short (1298 characters) and serves as a formal announcement of regulatory approval rather than a financial report or detailed presentation. It does not contain financial statements, management discussion, or detailed investor information. Therefore, it fits best as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2023-05-31 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.